IE 11 is not supported. For an optimal experience visit our site on another browser.

Revolutions Medical Hires David Rothkopf of SON Medical as Its Regulatory Compliance Consultant

/ Source: GlobeNewswire

CHARLESTON, S.C., April 5, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB:RMCP) is pleased to announce the hiring of a new regulatory compliance consultant, F. David Rothkopf, MSME, MBA, of SON Medical, LLC ("SON Medical"). Mr. Rothkopf has more than 20 years of professional strategic experience in the development of quality and regulatory controls of medical devices. He is currently the President and Founder of SON Medical, established in 2000 to offer quality, regulatory consulting assistance to the medical device industry.

Prior to starting SON Medical, Mr. Rothkopf was instrumental in starting three medical device companies. Mr. Rothkopf is also currently the President of MEDIcept, Inc., a whole blood and plasma consulting firm and was a Senior Quality Consultant at Medical Action Industries, Inc., a developer, manufacturer, marketer and supplier of a variety of disposable medical products. Prior to Mr. Rothkopf's entrepreneurial pursuits, he was the Vice President of Quality and Regulatory Affairs at Urovations, the Director of Quality at Uromed, Inc., and a project leader at Johnson and Johnson Professional.

"Over my career, I have assisted over 300 companies with the knowledge required to navigate the national and international regulatory paths. I am enthusiastic to be working with Revolutions Medical and to help them bring to the market their cutting edge RevVac Auto Retractable Vacuum Safety Syringes," stated Mr. Rothkopf. Over the past 15 years, Mr. Rothkopf has performed well over 350: ISO 13485 and FDA-style audits and submitted over 55 510(K) pre-market notifications and pre-market approvals (PMAs).

Further, along with other SON Medical personnel, he developed over 100 submissions. Mr. Rothkopf has leveraged his extensive quality assurance, regulatory, and clinical knowledge, along with his past successes with regulated bodies for his clients' advantage, by finding the most cost effective and efficient method to achieving full federal compliance. Mr. Rothkopf holds both a bachelor's and master's degree in mechanical engineering from Worcester Polytechnic Institute and a MBA from Boston University.

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac™ Safety Syringe (FDA cleared), safety blood drawing device; and the RevColorTM, RevDisplayTM and Rev3DTM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA cleared).

For additional information, please visit Revolutions Medical corporate website:

To be added to the Revolutions Medical investor email list, please email: with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook – visit:

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: Revolutions Medical Corporation Investor and Corporate Relations Gregory S. Lowe Acorn Management Partners President / Partner 678-368-4013